person · Reporting owner
ROSENWALD LINDSAY A MD
Disclosed activity across 6 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVENUE THERAPEUTICS, INC.ATXI · Entity 8537 | Director | September 23, 2024 | September 25, 2024 |
| Fortress Biotech, Inc.FBIO · Entity 6822 | Director · PRESIDENT, CEO & CHAIRMAN · 10% owner | March 18, 2026 | March 20, 2026 |
| Journey Medical CorpDERM · Entity 6273 | Director | June 25, 2026 | June 26, 2026 |
| MUSTANG BIO, INC.MBIO · Entity 8350 | Director | July 05, 2023 | July 07, 2023 |
| NATIONAL HOLDINGS CORPNHLD · Entity 142239 | 10% owner | September 12, 2016 | September 22, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVENUE THERAPEUTICS, INC.
Report date September 23, 2024 · Filed September 25, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.46 · Expires 2034-09-23 | Direct | 30,000 |
Reported balance
After 2024-09-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-09-23 · Grant · Acquired 30,000 · Balance 30,000 F1: The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2025; (ii) one-third of the shares subject to the option vest on January 1, 2026; and (iii) one-third of the shares subject to the option vest on January 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2025; (ii) one-third of the shares subject to the option vest on January 1, 2026; and (iii) one-third of the shares subject to the option vest on January 1, 2027.
Fortress Biotech, Inc.
Report date March 18, 2026 · Filed March 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, par value $0.001SEC Table I · non-derivative | Direct | 4,586,841 |
Reported balance
After 2026-03-18 transaction · row 1
1 source rowRow 1 · 2026-03-18 · Grant · Acquired 475,424 · Balance 4,586,841 F1: The Reporting Person was granted 475,424 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on March 18, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted 475,424 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on March 18, 2026.
Journey Medical Corp
Report date June 25, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 221,146 |
Reported balance
After 2026-06-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 10,000 · Balance 221,146 F1: On June 25, 2026, the reporting person was granted 10,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, which will vest in accordance with the following schedule: 10,000 shares on June 25, 2027. F2: Includes restricted stock units, which vest over various time periods. |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | IndirectSee Footnote | 176,470 |
Reported balance
Holding disclosure · report date 2026-06-25 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 176,470 F3: The shares are held by a limited liability company over which the reporting person, as managing member, is deemed to have voting and investment power. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 25, 2026, the reporting person was granted 10,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, which will vest in accordance with the following schedule: 10,000 shares on June 25, 2027.
F2: Includes restricted stock units, which vest over various time periods.
F3: The shares are held by a limited liability company over which the reporting person, as managing member, is deemed to have voting and investment power.
MUSTANG BIO, INC.
Report date July 05, 2023 · Filed July 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCK, PAR VALUE $0.0001SEC Table I · non-derivative | Direct | 60,525 |
Reported balance
After 2023-07-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-07-05 · Grant · Acquired 7,246 · Balance 60,525 F1: The Reporting Person was granted 7,246 restricted shares pursuant to the Issuer's 2016 Incentive Plan on July 5, 2023. The shares will vest on July 5, 2026, subject to the Reporting Person's continued service on the Issuer's board on such date. F2: Effective April 3, 2023, the Issuer effected a fifteen-for-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. F3: Includes restricted share units, which vest over various time periods. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted 7,246 restricted shares pursuant to the Issuer's 2016 Incentive Plan on July 5, 2023. The shares will vest on July 5, 2026, subject to the Reporting Person's continued service on the Issuer's board on such date.
F2: Effective April 3, 2023, the Issuer effected a fifteen-for-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split.
F3: Includes restricted share units, which vest over various time periods.
NATIONAL HOLDINGS CORP
Report date September 12, 2016 · Filed September 22, 2016
Jointly reported with FBIO Acquisition, Inc., Fortress Biotech, Inc., Opus Point Partners, LLC, Opus Point Healthcare Innovations (Offshore) Fund Ltd., WEISS MICHAEL S
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,037,482 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 7,037,482 F1: These securities are owned directly by FBIO Acquisition, Inc. ("FBIO Acquisition"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) FBIO Acquisition, (ii) Fortress Biotech, Inc. ("FBIO"), (iii) Opus Point Partners, LLC ("Opus Point Partners"), (iv) Opus Point Healthcare Innovations (Offshore) Fund Ltd. ("Opus Point Healthcare"), (v) Lindsay A. Rosenwald, M.D. and (vi) Michael S. Weiss (collectively, the "FBIO Group"), and indirectly by FBIO, by its ownership of FBIO Acquisition. Each of the members of the FBIO Group, other than FBIO Acquisition and FBIO, disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 371,584 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 371,584 F2: These securities are owned directly by Opus Point Partners, and indirectly by Dr. Rosenwald and Mr. Weiss, by their ownership in Opus Point Partners. Each of FBIO Acquisition, FBIO and Opus Point Healthcare disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 89,530 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 89,530 F3: These securities are owned directly by Opus Point Healthcare, and indirectly by Opus Point Partners and Dr. Rosenwald and Mr. Weiss, by their ownership in Opus Point Partners. Each of FBIO Acquisition and FBIO disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 44,884 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 44,884 F4: These securities are owned directly by Mr. Weiss. Each of other members of the FBIO Group disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 16,294 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 16,294 F5: These securities are owned directly by Dr. Rosenwald. Each of other members of the FBIO Group disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are owned directly by FBIO Acquisition, Inc. ("FBIO Acquisition"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) FBIO Acquisition, (ii) Fortress Biotech, Inc. ("FBIO"), (iii) Opus Point Partners, LLC ("Opus Point Partners"), (iv) Opus Point Healthcare Innovations (Offshore) Fund Ltd. ("Opus Point Healthcare"), (v) Lindsay A. Rosenwald, M.D. and (vi) Michael S. Weiss (collectively, the "FBIO Group"), and indirectly by FBIO, by its ownership of FBIO Acquisition. Each of the members of the FBIO Group, other than FBIO Acquisition and FBIO, disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F2: These securities are owned directly by Opus Point Partners, and indirectly by Dr. Rosenwald and Mr. Weiss, by their ownership in Opus Point Partners. Each of FBIO Acquisition, FBIO and Opus Point Healthcare disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F3: These securities are owned directly by Opus Point Healthcare, and indirectly by Opus Point Partners and Dr. Rosenwald and Mr. Weiss, by their ownership in Opus Point Partners. Each of FBIO Acquisition and FBIO disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F4: These securities are owned directly by Mr. Weiss. Each of other members of the FBIO Group disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F5: These securities are owned directly by Dr. Rosenwald. Each of other members of the FBIO Group disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Checkpoint Therapeutics, Inc.
Report date May 28, 2025 · Filed May 30, 2025
Section 16 reporting ended · disclosed 2025-05-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 157,007 |
Reported balance
After 2025-05-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-05-28 · Grant · Acquired 12,195 · Balance 157,007 F1: Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Rosenwald's continued service on the board. |
| COMMON STOCKSEC Table I · non-derivative | Direct | 207,007 |
Reported balance
After 2025-05-29 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-05-29 · Grant · Acquired 50,000 · Balance 207,007 |
| COMMON STOCKSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-05-30 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2025-05-30 · Other · Disposed 207,007 · Balance 0 F2: Disposed of in connection with an offer made pursuant to the Agreement and Plan of Merger, dated as of March 9, 2025 and as amended on April 14, 2025 (the "Merger Agreement"), in exchange for $4.10 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment ranging from $0.20 to $0.70 pursuant to certain milestone payments as defined in the Merger Agreement relating to the regulatory approval for cosibelimab in the European Union. The CVR milestone must be achieved within thirty-six (36) months after the date on which a marketing authorization application or equivalent application for cosibelimab receives a positive validation outcome by the European Medicines Agency. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Rosenwald's continued service on the board.
F2: Disposed of in connection with an offer made pursuant to the Agreement and Plan of Merger, dated as of March 9, 2025 and as amended on April 14, 2025 (the "Merger Agreement"), in exchange for $4.10 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment ranging from $0.20 to $0.70 pursuant to certain milestone payments as defined in the Merger Agreement relating to the regulatory approval for cosibelimab in the European Union. The CVR milestone must be achieved within thirty-six (36) months after the date on which a marketing authorization application or equivalent application for cosibelimab receives a positive validation outcome by the European Medicines Agency.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 26, 2026 20:14 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCommon Stock, $0.0001 par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-078266 · tm2619089-1_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,146 F1 · shares: On June 25, 2026, the reporting person was granted 10,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, which will vest in accordance with the following schedule: 10,000 shares on June 25, 2027. F2 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 20:05 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon stock, par value $0.001 | 475,424 | $0.00 | $0.00 |
DisclosureSEC source: 0000941841-26-000002 · form4-03202026_040304.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT, CEO & CHAIRMAN · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,586,841 F1 · shares: The Reporting Person was granted 475,424 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on March 18, 2026. Read SEC document |
| August 05, 2025 Filed Aug 7, 2025 21:18 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCommon Stock, $0.0001 par value | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-075272 · tm2522819-5_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,146 F1 · shares: On August 5, 2025, the reporting person was granted 50,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, which will vest in accordance with the following schedule: 16,667 shares on August 5, 2028, 16,667 shares on August 5, 2029 and 16,666 shares on August 5, 2030. F2 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| June 25, 2025 Filed Jul 8, 2025 01:50 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCommon Stock, $0.0001 par value | 7,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-066239 · tm2520050-4_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,146 F1 · shares: On June 25, 2025, the reporting person was granted 7,173 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, which will vest in full on June 25, 2026. F2 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| May 30, 2025 Filed May 30, 2025 15:19 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | OtherCOMMON STOCK | 207,007 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-054692 · tm2516581-6_4seq1.xml · nonDerivative · entry 3 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: Disposed of in connection with an offer made pursuant to the Agreement and Plan of Merger, dated as of March 9, 2025 and as amended on April 14, 2025 (the "Merger Agreement"), in exchange for $4.10 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment ranging from $0.20 to $0.70 pursuant to certain milestone payments as defined in the Merger Agreement relating to the regulatory approval for cosibelimab in the European Union. The CVR milestone must be achieved within thirty-six (36) months after the date on which a marketing authorization application or equivalent application for cosibelimab receives a positive validation outcome by the European Medicines Agency. Read SEC document |
| May 29, 2025 Filed May 30, 2025 15:19 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 50,000 | $1.29 | $64,500.00 |
DisclosureSEC source: 0001104659-25-054692 · tm2516581-6_4seq1.xml · nonDerivative · entry 2 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,007 Read SEC document |
| May 28, 2025 Filed May 30, 2025 15:19 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 12,195 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-054692 · tm2516581-6_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,007 F1 · balance_after: Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Rosenwald's continued service on the board. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:15 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon stock, par value $0.001 | 454,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000400 · form4-01032025_040103.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT, CEO & CHAIRMAN · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,111,417 F1 · shares: The Reporting Person was granted 454,153 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on January 1, 2025. Read SEC document |
| December 13, 2024 Filed Dec 18, 2024 02:32 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 12,638 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-129526 · tm2431396-6_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,812 F1 · shares: Represents previously-granted performance-based award that became vested upon achievement of a corporate milestone on December 13, 2024. F2 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 20:59 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantEmployee stock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0001104659-24-102840 · tm2424771-7_4seq1.xml · derivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-09-23 F1 · derivative.exercise_date: The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2025; (ii) one-third of the shares subject to the option vest on January 1, 2026; and (iii) one-third of the shares subject to the option vest on January 1, 2027. Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 20:45 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseWarrants to Purchase Common Stock · Derivative | 763,359 | $0.13 Strike: $1.84 | $95,419.88 |
DisclosureSEC source: 0001415889-24-023957 · form4-09252024_040901.xml · derivative · entry 2 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT, CEO & CHAIRMAN · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 763,359 Underlying: Common Stock · 763,359 shares Expires 2030-03-23 Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 20:45 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseCommon stock, par value $0.001 | 763,359 | $1.84 | $1,404,580.56 |
DisclosureSEC source: 0001415889-24-023957 · form4-09252024_040901.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT, CEO & CHAIRMAN · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,657,264 Read SEC document |
| July 11, 2024 Filed Jul 15, 2024 20:05 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseSERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | 5,000 | $7.48 | $37,417.50 |
DisclosureSEC source: 0001104659-24-079855 · tm2419471-1_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · President, CEO & Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,500 F1 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on July 11, 2024 was $7.35 to $7.49. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 09, 2024 Filed Jul 11, 2024 12:00 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseSERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | 5,000 | $7.39 | $36,971.00 |
DisclosureSEC source: 0001104659-24-079100 · tm2419219-1_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · President, CEO & Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,500 F1 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on July 9, 2024 was $7.25 to $7.48. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 08, 2024 Filed Jul 10, 2024 20:43 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCommon Stock, $0.0001 par value | 9,728 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-078968 · tm2419199-1_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,973 F1 · shares: On July 8, 2024, the reporting person was granted 9,728 restricted stock units pursuant to the Issuer's 2015 Stock Plan, which will vest in full on July 8, 2025. F2 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| July 08, 2024 Filed Jul 10, 2024 12:30 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseSERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | 5,000 | $7.35 | $36,764.50 |
DisclosureSEC source: 0001104659-24-078786 · tm2419164-1_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · President, CEO & Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,500 F1 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on July 8, 2024 was $7.29 to $7.47. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 28, 2024 Filed Jul 1, 2024 12:40 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseCOMMON STOCK, PAR VALUE $0.001 | 20,000 | $1.64 | $32,724.00 |
DisclosureSEC source: 0001104659-24-076591 · tm2418613-1_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · President, CEO & Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,893,905 Read SEC document |
| May 16, 2024 Filed May 20, 2024 21:00 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseCOMMON STOCK, PAR VALUE $0.001 | 10,000 | $1.76 | $17,589.00 |
DisclosureSEC source: 0001104659-24-063455 · tm2415000-2_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · President, CEO & Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,873,905 Read SEC document |
| May 14, 2024 Filed May 16, 2024 23:32 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-062664 · tm2414703-3_4seq1.xml · nonDerivative · entry 2 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,174 F3 · shares: The 50,000 shares of restricted Common Stock will vest according to the following schedule, subject to Mr. Rosenwald's continued service on the board on each date: one third on May 14, 2027, one third on May 14, 2028, and one third on May 14, 2029. F2 · balance_after: Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Rosenwald's continued service on the board. Read SEC document |
| May 14, 2024 Filed May 16, 2024 23:32 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 32,051 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-062664 · tm2414703-3_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,174 F1 · shares: The 32,051 shares of restricted Common Stock will vest on May 14, 2027, subject to Mr. Rosenwald's continued service on the board on such date. F2 · balance_after: Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Rosenwald's continued service on the board. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 11:00 UTC | Journey Medical Corp DERM · Entity 6273 | PurchaseCommon Stock, $0.0001 par value | 10,000 | $3.04 | $30,400.00 |
DisclosureSEC source: 0001104659-24-039354 · tm249895-1_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,245 F1 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| March 22, 2024 Filed Mar 25, 2024 20:01 UTC | Journey Medical Corp DERM · Entity 6273 | PurchaseCommon Stock, $0.0001 par value | 20,000 | $3.40 | $68,000.00 |
DisclosureSEC source: 0001104659-24-038431 · tm249705-1_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,245 F1 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 13:15 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseCOMMON STOCK, PAR VALUE $0.001 | 50,000 | $2.38 | $118,770.00 |
DisclosureSEC source: 0001104659-24-002464 · tm242385-1_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · President, CEO & Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,863,905 Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:46 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 216,465 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-000898 · tm241755-10_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · President, CEO & Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,813,905 F1 · shares: The Reporting Person was granted 216,465 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on January 1, 2024. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 22:50 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseWarrants to purchase Common Stock · Derivative | 1,567,515 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001104659-23-119188 · tm2330934-2_4seq1.xml · derivative · entry 2 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · President, CEO & Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,567,515 Underlying: Common Stock · 1,567,515 shares Expires 2028-11-14 F2 · price: The shares of common stock and warrants to purchase common stock reflect on this Form 4 were purchased as units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock, at a price per unit of $1.70. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 22:50 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseCOMMON STOCK, PAR VALUE $0.001 | 1,567,515 | $1.70 | $2,664,775.50 |
DisclosureSEC source: 0001104659-23-119188 · tm2330934-2_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · President, CEO & Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,597,440 F1 · shares: Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split. F2 · price: The shares of common stock and warrants to purchase common stock reflect on this Form 4 were purchased as units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock, at a price per unit of $1.70. F1 · balance_after: Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 12:20 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseCOMMON STOCK, PAR VALUE $0.001 | 100,000 | $0.28 | $28,330.00 |
DisclosureSEC source: 0001104659-23-104099 · tm2327003-1_4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · President, CEO & Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,449,091 Read SEC document |
| September 08, 2023 Filed Sep 12, 2023 13:03 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 348,675 | $0.72 | $251,046.00 |
DisclosureSEC source: 0001437749-23-025643 · rdgdoc.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 354,318 Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 17:25 UTC | Journey Medical Corp DERM · Entity 6273 | PurchaseCommon Stock, par value $0.0001 per share | 100,000 | $2.23 | $223,000.00 |
DisclosureSEC source: 0001104659-23-099229 · tm2325760-1_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,245 F1 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| August 18, 2023 Filed Aug 21, 2023 12:30 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseSERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | 10,000 | $9.34 | $93,400.00 |
DisclosureSEC source: 0001104659-23-093700 · tm2324200-1_4seq1.xml · nonDerivative · entry 2 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · President, CEO & Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,500 Read SEC document |
| August 17, 2023 Filed Aug 21, 2023 12:30 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseSERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | 10,000 | $11.75 | $117,500.00 |
DisclosureSEC source: 0001104659-23-093700 · tm2324200-1_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · President, CEO & Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,500 Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 20:06 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 7,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-079114 · tm2320790-4_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,525 F1 · shares: The Reporting Person was granted 7,246 restricted shares pursuant to the Issuer's 2016 Incentive Plan on July 5, 2023. The shares will vest on July 5, 2026, subject to the Reporting Person's continued service on the Issuer's board on such date. F2 · shares: Effective April 3, 2023, the Issuer effected a fifteen-for-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. F2 · balance_after: Effective April 3, 2023, the Issuer effected a fifteen-for-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. F3 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 20:08 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantEmployee stock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001104659-23-078096 · tm2320488d4_4seq1.xml · derivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-06-30 F1 · derivative.exercise_date: The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2024; (ii) one-third of the shares subject to the option vest on January 1, 2025; and (iii) one-third of the shares subject to the option vest on January 1, 2026. F2 · derivative.underlying_shares: Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. F2 · balance_after: Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. Read SEC document |
| June 13, 2023 Filed Jun 16, 2023 00:00 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 17,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-071759 · tm2318836-4_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,123 F1 · shares: The 17,483 shares of restricted Common Stock will vest on June 13, 2026, subject to Dr. Rosenwald's continued service on the board on such date. F2 · balance_after: Includes restricted shares of Common Stock which vest over various time periods, subject to Dr. Rosenwald's continued service on the board. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:10 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseCOMMON STOCK, PAR VALUE $0.001 | 2,395,209 | $0.84 | $1,999,999.52 |
DisclosureSEC source: 0001104659-23-021617 · tm236803-4_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · President, CEO & Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,349,091 Read SEC document |
| January 01, 2023 Filed Jan 5, 2023 02:28 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 1,219,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-001103 · tm231728-9_4seq1.xml · nonDerivative · entry 2 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · President, CEO & Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,953,882 F2 · shares: The Reporting Person was granted 1,219,294 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on January 1, 2023. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 12:31 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseCOMMON STOCK, PAR VALUE $0.001 | 100,000 | $0.68 | $67,960.00 |
DisclosureSEC source: 0001104659-22-124392 · tm2231935-1_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT, CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,730,324 Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 21:18 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseCOMMON STOCK, PAR VALUE $0.001 | 5,000 | $0.56 | $2,800.00 |
DisclosureSEC source: 0001104659-22-124108 · tm2231877-2_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT, CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,630,324 F1 · shares: Shares acquired as purchases made under the Issuer's Employee Stock Purchase Plan ("ESPP") during the ESPP offering period. Under the ESPP, 5,000 shares is the maximum amount an individual employee may purchase during an offering period. Read SEC document |
| October 21, 2022 Filed Oct 24, 2022 12:00 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseCOMMON STOCK, PAR VALUE $0.001 | 100,000 | $0.70 | $69,500.00 |
DisclosureSEC source: 0001104659-22-110780 · tm2228777-1_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT, CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,625,324 Read SEC document |
| September 13, 2022 Filed Apr 3, 2023 20:50 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | PurchaseCOMMON STOCK, PAR VALUE $0.0001 | 5,000 | $0.52 | $2,582.00 |
DisclosureSEC source: 0001104659-23-040932 · tm2311237-5_4seq1.xml · nonDerivative · entry 3 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 299,181 F1 · shares: Shares acquired as purchases made under the Issuer's Employee Stock Purchase Plan ("ESPP") during the ESPP offering period. F2 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| July 29, 2022 Filed Apr 3, 2023 20:50 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 71,664 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-040932 · tm2311237-5_4seq1.xml · nonDerivative · entry 2 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 294,181 F3 · shares: The Reporting Person was granted 71,664 restricted shares pursuant to the Issuer's 2016 Incentive Plan on July 29, 2022. The shares will vest on June 17, 2025, subject to the Reporting Person's continued service on the Issuer's board on such date. F2 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 13:40 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCommon Stock, par value $0.0001 per share | 14,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-082291 · tm2221508-7_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,245 F1 · shares: On July 21, 2022, the reporting person was granted 14,245 restricted stock units pursuant to the Issuer's 2015 Stock Plan, which will vest in full on July 21, 2023. F2 · balance_after: Includes 14,245 restricted stock units, which will vest as set forth in footnote 1. Read SEC document |
| June 16, 2022 Filed Jun 25, 2022 01:54 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 47,619 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-074466 · tm2219319-3_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,401 F1 · shares: The 47,619 shares of restricted Common Stock will vest on June 16, 2025, subject to Dr. Rosenwald's continued service on the board on such date. F2 · balance_after: Includes restricted shares of Common Stock which vest over various time periods, subject to Dr. Rosenwald's continued service on the board. Read SEC document |
| June 01, 2022 Filed Jan 5, 2023 02:28 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 4,264 | $0.73 | $3,112.72 |
DisclosureSEC source: 0001104659-23-001103 · tm231728-9_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · President, CEO & Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,734,588 F1 · shares: These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 18, 2022 Filed Apr 3, 2023 20:50 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | PurchaseCOMMON STOCK, PAR VALUE $0.0001 | 4,094 | $0.74 | $3,025.47 |
DisclosureSEC source: 0001104659-23-040932 · tm2311237-5_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,517 F1 · shares: Shares acquired as purchases made under the Issuer's Employee Stock Purchase Plan ("ESPP") during the ESPP offering period. F2 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| January 01, 2022 Filed Apr 29, 2022 20:22 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 1,102,986 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-053615 · tm2213913-6_4seq1.xml · nonDerivative · entry 5 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT, CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,525,324 F4 · kind: The reporting person was granted 1,102,986 restricted shares pursuant to the issuer's Long-Term Incentive Plan on January 1, 2022. Read SEC document |
| December 01, 2021 Filed Apr 29, 2022 20:22 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 1,250 | $2.42 | $3,025.00 |
DisclosureSEC source: 0001104659-22-053615 · tm2213913-6_4seq1.xml · nonDerivative · entry 4 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT, CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,422,338 F1 · kind: Shares acquired as purchases made under the Issuer's Employee Stock Purchase Plan ("ESPP") during the ESPP offering period. Read SEC document |
| November 16, 2021 Filed Apr 29, 2022 20:22 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | OtherCOMMON STOCK, PAR VALUE $0.001 | 4,619 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-053615 · tm2213913-6_4seq1.xml · nonDerivative · entry 3 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT, CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,421,088 F3 · kind: The shares were issued upon the consummation of Journey Medical Corporation ("Journey's") initial public offering as a partial dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey's 8% Cumulative Convertible Class A Preferred Stock. Read SEC document |
| September 30, 2021 Filed Apr 29, 2022 20:22 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | OtherCOMMON STOCK, PAR VALUE $0.001 | 8,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-053615 · tm2213913-6_4seq1.xml · nonDerivative · entry 2 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT, CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,416,469 F2 · kind: The shares were issued as a dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey Medical Corporation's 8% Cumulative Convertible Class A Preferred Stock. Read SEC document |
| August 31, 2021 Filed Sep 24, 2021 21:25 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK | 1,170 | $2.58 | $3,018.60 |
DisclosureSEC source: 0001104659-21-119389 · tm2128458-2_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,423 F1 · shares: These shares were acquired under the Mustang Bio, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on March 1, 2021 and ending on August 31, 2021 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on August 31, 2021 (the purchase date of the offering period). F2 · balance_after: Includes restricted shares, which vest over various time periods. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.